Published in Int J Cancer on November 15, 1986
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol (1991) 2.38
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol (1991) 1.50
Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol (1988) 1.44
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A (1990) 1.31
Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion. J Cell Biol (1989) 1.14
Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest (1991) 1.09
Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonuclear leucocyte elastase in the progression of human breast cancer. Br J Cancer (1994) 0.94
Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer (1991) 0.93
Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. Br J Cancer (1995) 0.83
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells. Br J Cancer (1996) 0.82
Procoagulant activity of human tumours: existence of Xa and thrombin-like activities. Br J Cancer (1990) 0.76
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A (1992) 5.94
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med (1998) 3.17
The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med (1998) 2.55
Growth of mouse megakaryocyte colonies in vitro. Proc Natl Acad Sci U S A (1975) 2.38
The tetraspanin CD63/lamp3 cycles between endocytic and secretory compartments in human endothelial cells. Mol Biol Cell (2000) 2.12
In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature (1974) 1.96
Antibody-dependent cell-mediated cytotoxicity: heterogeneity of effector cells in human peripheral blood. Scand J Immunol (1975) 1.94
CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol (1995) 1.93
Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem (1989) 1.93
Leishmania tropica: pathogenicity and in vitro macrophage function in strains of inbred mice. Exp Parasitol (1979) 1.88
Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med (1983) 1.85
Specific antibody within lymphoid germinal center cells of mice after primary immunization with horseradish peroxidase: a light and electron microscopic study. J Exp Med (1970) 1.75
LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem (1999) 1.75
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer (1984) 1.72
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood (1988) 1.68
Pathophysiology of endotoxin shock in the primate. Am J Obstet Gynecol (1970) 1.65
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ (1991) 1.65
T cell antigen receptor expression in athymic (nu/nu) mice. Evidence for an oligoclonal beta chain repertoire. J Exp Med (1987) 1.61
Age-associated increase in expression of the T cell surface markers Thy-1, Lyt-1, and Lyt-2 in congenitally athymic (nu/nu) mice: analysis by flow microfluorometry. J Immunol (1981) 1.48
Isolation and characterization of urokinase from human plasma. J Biol Chem (1982) 1.47
Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest (2001) 1.46
Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett (2000) 1.45
Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood (1984) 1.44
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem (1990) 1.43
Oxygenation and differentiation in multicellular spheroids of human colon carcinoma. Cancer Res (1986) 1.42
ApoE genotype does not affect plasma tPA and PAI-1 antigen levels. Am J Med Genet (1997) 1.40
Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res (1997) 1.39
Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. Proc Natl Acad Sci U S A (1997) 1.38
Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. EMBO J (1989) 1.38
Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb (1993) 1.38
Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest (1997) 1.37
Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J (1980) 1.37
Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood (1993) 1.35
Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem (1986) 1.33
Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol (1987) 1.32
Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells. J Cell Biol (1987) 1.32
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A (1990) 1.31
Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood (1987) 1.29
Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia. J Pathol (1998) 1.27
Generation of cytotoxic T lymphocytes in vitro. IV. Functional activation of memory cells in the absence of DNA synthesis. J Exp Med (1975) 1.26
Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost (1984) 1.23
Abnormal distribution of T cell subsets in athymic mice. J Immunol (1986) 1.22
Necrosis of skin induced by coumarin in a patient deficient in protein S. BMJ (1989) 1.20
The two promoters of the mouse alpha-amylase gene Amy-1a are differentially activated during parotid gland differentiation. Cell (1985) 1.19
[Incidence of intramural digestive system hematoma in anticoagulation. Epidemiologic study and clinical aspects of 59 cases observed in Switzerland (1970-1975)]. Schweiz Med Wochenschr (1983) 1.19
The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3. Eur J Biochem (1996) 1.16
Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion. J Cell Biol (1989) 1.14
Triabin, a highly potent exosite inhibitor of thrombin. J Biol Chem (1995) 1.14
Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost (1989) 1.12
Primary structure and properties of helothermine, a peptide toxin that blocks ryanodine receptors. Biophys J (1995) 1.12
Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer (1998) 1.11
Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (1995) 1.11
Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry (2001) 1.10
IgG immunoglobulin in the wall of post-capillary venules: possible relationship to lymphocyte recirculation. Immunology (1971) 1.10
Complications following total knee replacement. Clin Orthop Relat Res (1977) 1.09
Immunohistological evidence, obtained with monoclonal antibodies, of small intestinal brush border hydrolases in human colon cancers and foetal colons. Int J Cancer (1984) 1.09
Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem (1998) 1.08
Establishment of a cell line (Co-115) from a human colon carcinoma transplanted into nude mice. Cancer Res (1976) 1.08
Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost (1999) 1.08
The bursa of Fabricius: a central organ providing for contact between the lymphoid system and intestinal content. Cell Immunol (1974) 1.07
Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5' flanking region. J Biol Chem (1985) 1.07
Transfer of humoral secretory and cellular immunity from mother to offspring. Curr Top Pathol (1979) 1.06
Interaction of urokinase-type plasminogenactivator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett (1993) 1.06
p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer (2000) 1.04
New androgen response elements in the murine pem promoter mediate selective transactivation. Mol Endocrinol (2001) 1.04
Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest (1982) 1.04
A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood (1991) 1.03
Thromboembolic disease in patients undergoing total knee replacement. J Bone Joint Surg Am (1976) 1.03
Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. J Cell Biol (1988) 1.03
An inhibitor of collagen-induced platelet aggregation from the saliva of Triatoma pallidipennis. J Biol Chem (1994) 1.03
Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer (2000) 1.00
The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth. Oncogene (1995) 1.00
Establishment of two rabbit mammary epithelial cell lines with distinct oncogenic potential and differentiated phenotype after microinjection of transforming genes. Mol Cell Biol (1986) 1.00
The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg (1975) 1.00
Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J Exp Med (1988) 1.00
Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res (1993) 0.99
Cytolytic T lymphocyte precursor cells in congenitally athymic C57BL/6 nu/nu mice: quantitation, enrichment, and specificity. J Immunol (1981) 0.99
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol (2001) 0.99
Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet (1992) 0.99
The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemost (1986) 0.98
Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2. Cancer Res (1992) 0.98
Splice variants of the human EP3 receptor for prostaglandin E2. Eur J Biochem (1995) 0.98
Mechanism of target cell lysis of cytolytic T lymphocytes. I. Characterization of specific lymphocyte-target cell conjugates separated by velocity sedimentation. Eur J Immunol (1977) 0.97